Astellas Pharma US has launched ASTAGRAF XL (tacrolimus extended-release capsules), the first once-daily oral tacrolimus formulation, in the US market.
The new product is indicated for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction.
Astellas Pharma US president James Robinson said the availability of ASTAGRAF XL marks a significant moment for the transplantation community, giving new adult kidney transplant recipients an additional option in their immunosuppressant care.
"Astellas has long been a leader in the field of transplant immunology, and we are proud to continue to advance care for transplant recipients," Robinson added.
A 0.15mg/kg once-daily (pre-operative) and 0.2mg/kg once-daily (post-operative) are recommended starting dose of ASTAGRAF XL with basiliximab induction.
The product is available in 0.5mg, 1mg and 5mg capsules.